<DOC>
	<DOCNO>NCT00709475</DOCNO>
	<brief_summary>This study conduct Asia . The aim observational study evaluate incidence serious adverse drug reaction use insulin detemir normal clinical practice condition Gulf country</brief_summary>
	<brief_title>Observational Safety Study Subjects Using LevemirÂ® ( Insulin Detemir ) Treatment Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>After physician decision make use insulin detemir therapy , subject Type 2 diabetes eligible study , include newlydiagnosed subject never receive insulin insulin analogue . The selection subject discretion individual physician Subjects unlikely comply protocol , e.g . uncooperative attitude , inability return final visit ; Subjects currently treat insulin detemir ; Subjects previously enrol study study relate NovoMix 30 ; Subjects hypersensitivity insulin detemir excipients ; Women pregnant , breast feeding intention become pregnant within next 8 month .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>